HIGHLIGHTS
- who: Charlotte Ouimet and colleagues from the McGill University, Biomedical Ethics Unit, Montreal, QC, Canada, The Anticancer Fund, Brussels have published the Article: Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study, in the Journal: PLOS ONE of August/23,/2022
- what: The authors aimed to compare the clinical impact of research efforts started after approval with those started before for cancer drugs. cancer drugs that were initially FDA approved between 2005 and 2017. When multiple trials were cited as pivotal for a single indication, the trial with the largest effect . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.